ICH S5 Reproductive Toxicity Testing Guidelines
E1538044
UNEXPLORED
The ICH S5 Reproductive Toxicity Testing Guidelines are international standards that outline how to evaluate the potential effects of pharmaceuticals on fertility, embryo-fetal development, and pre- and postnatal development to support safe drug use in humans.
All labels observed (1)
| Label | Occurrences |
|---|---|
| ICH S5 Reproductive Toxicity Testing Guidelines canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T22458037 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: ICH S5 Reproductive Toxicity Testing Guidelines Context triple: [ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, relatedTo, ICH S5 Reproductive Toxicity Testing Guidelines]
-
A.
ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
ICH M3(R2) is an international guideline that harmonizes requirements for nonclinical safety studies needed to support the initiation and progression of human clinical trials and the marketing authorization of pharmaceuticals.
-
B.
Experimental Toxicology and ZEBET
Experimental Toxicology and ZEBET is a specialized section of Germany’s Federal Institute for Risk Assessment focused on experimental toxicology and the development and promotion of alternative methods to animal testing.
-
C.
ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals is an international guideline that outlines the nonclinical safety testing requirements for biotechnological products such as therapeutic proteins and monoclonal antibodies to support their clinical development and marketing authorization.
-
D.
ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
-
E.
Toxicology in the 21st Century program
The Toxicology in the 21st Century program is a U.S. research initiative that uses modern high-throughput and computational methods to improve the prediction of chemical toxicity and reduce reliance on traditional animal testing.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: ICH S5 Reproductive Toxicity Testing Guidelines Target entity description: The ICH S5 Reproductive Toxicity Testing Guidelines are international standards that outline how to evaluate the potential effects of pharmaceuticals on fertility, embryo-fetal development, and pre- and postnatal development to support safe drug use in humans.
-
A.
ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
ICH M3(R2) is an international guideline that harmonizes requirements for nonclinical safety studies needed to support the initiation and progression of human clinical trials and the marketing authorization of pharmaceuticals.
-
B.
Experimental Toxicology and ZEBET
Experimental Toxicology and ZEBET is a specialized section of Germany’s Federal Institute for Risk Assessment focused on experimental toxicology and the development and promotion of alternative methods to animal testing.
-
C.
ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals is an international guideline that outlines the nonclinical safety testing requirements for biotechnological products such as therapeutic proteins and monoclonal antibodies to support their clinical development and marketing authorization.
-
D.
ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
-
E.
Toxicology in the 21st Century program
The Toxicology in the 21st Century program is a U.S. research initiative that uses modern high-throughput and computational methods to improve the prediction of chemical toxicity and reduce reliance on traditional animal testing.
- F. None of above. chosen
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.
ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
→
relatedTo
→
ICH S5 Reproductive Toxicity Testing Guidelines
ⓘ